![Kate Millson MIScT BSc (Hons)](https://profiles-cardiff.imgix.net/attachments/936?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Kate Millson
(she/her)
MIScT BSc (Hons)
Teams and roles for Kate Millson
Data Manager, Division of Psychological Medicine and Clinical Neurosciences
Overview
Currently I am Data Manager for the Psychosis Research Theme within the Centre for Neuropsychiatric Genetics and Genomics. I oversee the collation and governance of data from major grants and manage its curation and use on research projects, and I am responsible for the implementation of Data Management Plans for clinical, demographic and genomic data. This role provides the privileged opportunity to work with directly and in collaboration with multiple international leaders in psychiatric research.
My previous role was in the Genomics Research Hub in the School of Biosciences. There I was responsible for the generation of high-quality Next-Generation sequencing data for a diverse range of projects from biomedicine to ecology.
Prior to my position with Genomics Research Hub, I was Research Manager for the Alzheimer's Research Group. I was responsible for the operation of the Alzheimer’s Disease Genetics Team, planning, organising and delivering projects both within the University and in collaboration with world-renowned scientists. I was also responsible for a large part of research funding and grant management and provided professional advice and guidance on research sample management and Human Tissue Act compliance processes and procedures.
Prior to my management role, I was primarily laboratory based and led several laboratory research projects for the Parkinson's Research Team.
I am a member of the Institute of Science and Technology and have been awarded professional registration (RSci) by the Science Council.
Publication
2025
- Harvey, J. et al., 2025. Epigenetic insights into neuropsychiatric and cognitive symptoms in Parkinson's disease: A DNA co-methylation network analysis.. npj Parkinson's Disease 11 (1), pp.39. (10.1038/s41531-025-00877-5)
- Nicolas, A. et al., 2025. Transferability of European-derived Alzheimer's disease polygenic risk scores across multiancestry populations. Nature Genetics 57 , pp.1598-1610. (10.1038/s41588-025-02227-w)
2024
- Tan, M. M. X. et al., 2024. Genome-wide determinants of mortality and motor progression in Parkinson’s disease. npj Parkinson's Disease 10 (1) 113. (10.1038/s41531-024-00729-8)
- Wu, L. Y. et al., 2024. Investigation of the genetic aetiology of Lewy body diseases with and without dementia. Brain Communications 6 (4) fcae190. (10.1093/braincomms/fcae190)
2023
- Real, R. et al., 2023. Association between the LRP1B and APOE loci in the development of Parkinson’s disease dementia. Brain 146 (5), pp.1873-1887. (10.1093/brain/awac414)
- Winchester, L. et al., 2023. Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and cerebrospinal fluid. Brain Communications 5 (1) fcac343. (10.1093/braincomms/fcac343)
2022
- Aggarwal, D. et al., 2022. Genomic assessment of quarantine measures to prevent SARS-CoV-2 importation and transmission. Nature Communications 13 1012. (10.1038/s41467-022-28371-z)
- Aggarwal, D. et al., 2022. Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission. Nature Communications 13 (1) 751. (10.1038/s41467-021-27942-w)
- Bellenguez, C. et al., 2022. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics 54 (4), pp.412-436. (10.1038/s41588-022-01024-z)
- Eales, O. et al., 2022. SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2. BMC Infectious Diseases 22 (1) 647. (10.1186/s12879-022-07628-4)
- Kläser, K. et al., 2022. COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study. Scientific Reports 12 (1) 10904. (10.1038/s41598-022-14016-0)
- Nickbakhsh, S. et al., 2022. Genomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning. Scientific Reports 12 (1) 11735. (10.1038/s41598-022-15661-1)
- Willett, B. J. et al., 2022. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology 7 , pp.1161-1179. (10.1038/s41564-022-01143-7)
2021
- Davies, N. G. et al., 2021. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372 (6538) eabg3055. (10.1126/science.abg3055)
- de Rojas, I. et al., 2021. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications 12 (1) 3417. (10.1038/s41467-021-22491-8)
- Lythgoe, K. A. et al., 2021. SARS-CoV-2 within-host diversity and transmission. Science 372 (6539) eabg0821. (10.1126/science.abg0821)
- Tan, M. M. et al., 2021. Genome-wide association studies of cognitive and motor progression in Parkinson's disease. Movement Disorders 36 (2), pp.424-433. (10.1002/mds.28342)
2020
- Alm, E. et al., 2020. Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. Eurosurveillance 25 (32) 2001410. (10.2807/1560-7917.ES.2020.25.32.2001410)
2019
- Tan, M. M. et al., 2019. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. Brain 142 (9), pp.2828-2844. (10.1093/brain/awz191)
2018
- Malek, N. et al., 2018. Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study. Journal of Neurology, Neurosurgery and Psychiatry 89 (7), pp.702-709. (10.1136/jnnp-2017-317348)
2016
- Malek, N. et al., 2016. Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson's disease patients. Acta Neurologica Scandinavica 134 (4), pp.271-276. (10.1111/ane.12538)
2015
- Malek, N. et al., 2015. Tracking Parkinson's: study design and baseline patient data. Journal of Parkinson's Disease 5 (4), pp.947-959. (10.3233/JPD-150662)
Articles
- Aggarwal, D. et al., 2022. Genomic assessment of quarantine measures to prevent SARS-CoV-2 importation and transmission. Nature Communications 13 1012. (10.1038/s41467-022-28371-z)
- Aggarwal, D. et al., 2022. Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission. Nature Communications 13 (1) 751. (10.1038/s41467-021-27942-w)
- Alm, E. et al., 2020. Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. Eurosurveillance 25 (32) 2001410. (10.2807/1560-7917.ES.2020.25.32.2001410)
- Bellenguez, C. et al., 2022. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics 54 (4), pp.412-436. (10.1038/s41588-022-01024-z)
- Davies, N. G. et al., 2021. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372 (6538) eabg3055. (10.1126/science.abg3055)
- de Rojas, I. et al., 2021. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications 12 (1) 3417. (10.1038/s41467-021-22491-8)
- Eales, O. et al., 2022. SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2. BMC Infectious Diseases 22 (1) 647. (10.1186/s12879-022-07628-4)
- Harvey, J. et al., 2025. Epigenetic insights into neuropsychiatric and cognitive symptoms in Parkinson's disease: A DNA co-methylation network analysis.. npj Parkinson's Disease 11 (1), pp.39. (10.1038/s41531-025-00877-5)
- Kläser, K. et al., 2022. COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study. Scientific Reports 12 (1) 10904. (10.1038/s41598-022-14016-0)
- Lythgoe, K. A. et al., 2021. SARS-CoV-2 within-host diversity and transmission. Science 372 (6539) eabg0821. (10.1126/science.abg0821)
- Malek, N. et al., 2016. Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson's disease patients. Acta Neurologica Scandinavica 134 (4), pp.271-276. (10.1111/ane.12538)
- Malek, N. et al., 2015. Tracking Parkinson's: study design and baseline patient data. Journal of Parkinson's Disease 5 (4), pp.947-959. (10.3233/JPD-150662)
- Malek, N. et al., 2018. Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study. Journal of Neurology, Neurosurgery and Psychiatry 89 (7), pp.702-709. (10.1136/jnnp-2017-317348)
- Nickbakhsh, S. et al., 2022. Genomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning. Scientific Reports 12 (1) 11735. (10.1038/s41598-022-15661-1)
- Nicolas, A. et al., 2025. Transferability of European-derived Alzheimer's disease polygenic risk scores across multiancestry populations. Nature Genetics 57 , pp.1598-1610. (10.1038/s41588-025-02227-w)
- Real, R. et al., 2023. Association between the LRP1B and APOE loci in the development of Parkinson’s disease dementia. Brain 146 (5), pp.1873-1887. (10.1093/brain/awac414)
- Tan, M. M. X. et al., 2024. Genome-wide determinants of mortality and motor progression in Parkinson’s disease. npj Parkinson's Disease 10 (1) 113. (10.1038/s41531-024-00729-8)
- Tan, M. M. et al., 2021. Genome-wide association studies of cognitive and motor progression in Parkinson's disease. Movement Disorders 36 (2), pp.424-433. (10.1002/mds.28342)
- Tan, M. M. et al., 2019. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. Brain 142 (9), pp.2828-2844. (10.1093/brain/awz191)
- Willett, B. J. et al., 2022. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology 7 , pp.1161-1179. (10.1038/s41564-022-01143-7)
- Winchester, L. et al., 2023. Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and cerebrospinal fluid. Brain Communications 5 (1) fcac343. (10.1093/braincomms/fcac343)
- Wu, L. Y. et al., 2024. Investigation of the genetic aetiology of Lewy body diseases with and without dementia. Brain Communications 6 (4) fcae190. (10.1093/braincomms/fcae190)
Research
Currently I am Data Manager for the Psychosis Research Theme within the Centre for Neuropsychiatric Genetics and Genomics.
My previous role within the Genome Hub at Cardiff School of Biosciences was as a senior technician, generating Next-Generation sequencing data for a diverse range of projects from biomedicine to ecology.
As Research Manager with the Alzheimer's Disease Research Group I was involved in many projects related to Alzheimer's and Dementia research, both within Cardiff University and also large international collaborations.
Prior to my management role, my research projects investigated the genetic basis of Parkinson's disease, where I used a diverse range of complex techniques in order to generate high quality biological data which is then used for statistical analysis.
Biography
2024 - Present: Data Manager, Psychosis Research Group, Division of Psychological Medicine & Clinical Neurosciences
2020 - 2024 Senior Technician (Genome Research Hub), School of Biosciences.
2019 - 2020: Research Manager, Alzheimer's Research Group, Division of Psychological Medicine & Clinical Neurosciences
2018 - 2019: Sample Co-Ordinator, Alzheimer's Research Group, Division of Psychological Medicine & Clinical Neurosciences
2012 - 2018: Senior Research Technician, Parkinson's Research Group, Division of Psychological Medicine & Clinical Neurosciences
2010 - 2012: Research Technician, Core Facility, Division of Psychological Medicine & Clinical Neurosciences
Honours and awards
Registered Scientist (RSci), awarded by Science Council (2018)
Professional memberships
Member of the Institute of Science and Technology
Contact Details
+44 29206 88362
Sir Martin Evans Building, Room 2.01 - Desk 09, Museum Avenue, Cardiff, CF10 3AX
Research themes
Specialisms
- Epigenetics
- Epigenomics
- Genetics
- Genome methylation
- Data management